{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T12:40:48Z","timestamp":1675514448112},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00393-022-01264-8","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T18:28:53Z","timestamp":1662748133000},"page":"56-63","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geschichte der Biologikatherapie bei axialer Spondyloarthritis\u00a0\u2013 Teil\u00a02"],"prefix":"10.1007","volume":"82","author":[{"given":"Joachim","family":"Sieper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"1264_CR1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten\u00a0D, Baraliakos\u00a0X, Braun\u00a0J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 382:1705\u20131713","journal-title":"Lancet"},{"key":"1264_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten\u00a0D, Ostergaard\u00a0M, Wei\u00a0JC et al (2018) Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a\u00a0randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2\u00a0study. Ann Rheum Dis 77:1295\u20131302","journal-title":"Ann Rheum Dis"},{"key":"1264_CR3","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten\u00a0D, Sieper\u00a0J, Braun\u00a0J et al (2015) Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis. N\u00a0Engl J Med 373:2534\u20132548","journal-title":"N Engl J Med"},{"key":"1264_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos\u00a0X, Ostergaard\u00a0M, Gensler\u00a0LS et\u00a0al (2020) Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a\u00a0randomized, phase IIIb study (SURPASS). Clin Drug Investig 40:269\u2013278","journal-title":"Clin Drug Investig"},{"key":"1264_CR5","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1093\/rheumatology\/keaa212","volume":"59","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos\u00a0X, Tsiami\u00a0S, Redeker\u00a0I et al (2020) Early recognition of patients with axial spondyloarthritis-evaluation of referral strategies in primary care. Rheumatology (Oxford) 59:3845\u20133852","journal-title":"Rheumatology (Oxford)"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/ard.2006.068734","volume":"66","author":"HC Brandt","year":"2007","unstructured":"Brandt\u00a0HC, Spiller\u00a0I, Song\u00a0IH et\u00a0al (2007) Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 66:1479\u20131484","journal-title":"Ann Rheum Dis"},{"key":"1264_CR7","first-page":"118","volume":"29","author":"J Brandt","year":"2002","unstructured":"Brandt\u00a0J, Haibel\u00a0H, Reddig\u00a0J et al (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J\u00a0Rheumatol 29:118\u2013122","journal-title":"J Rheumatol"},{"key":"1264_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/rheumatology\/ket115","volume":"52","author":"A Braun","year":"2013","unstructured":"Braun\u00a0A, Gnann\u00a0H, Saracbasi\u00a0E et al (2013) Optimizing the identification of patients with axial spondyloarthritis in primary care\u2014the case for a\u00a0two-step strategy combining the most relevant clinical items with HLA B27. Rheumatology (Oxford) 52:1418\u20131424","journal-title":"Rheumatology (Oxford)"},{"key":"1264_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3899\/jrheum.130959","volume":"42","author":"J Braun","year":"2015","unstructured":"Braun\u00a0J, Baraliakos\u00a0X, Kiltz\u00a0U et\u00a0al (2015) Classification and diagnosis of axial spondyloarthritis\u2014What is the clinically relevant difference? J\u00a0Rheumatol 42:31\u201338","journal-title":"J Rheumatol"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun\u00a0J, Brandt\u00a0J, Listing\u00a0J et\u00a0al (2002) Treatment of active ankylosing spondylitis with infliximab: a\u00a0randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/ard.2006.052878","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun\u00a0J, Zochling\u00a0J, Baraliakos\u00a0X et\u00a0al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a\u00a0multicentre randomised controlled trial. Ann Rheum Dis 65:1147\u20131153","journal-title":"Ann Rheum Dis"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar\u00a0A, Blanco\u00a0R, Dokoupilova\u00a0E et al (2021) Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a\u00a0randomized, placebo-controlled phase III study. Arthritis Rheumatol 73:110\u2013120","journal-title":"Arthritis Rheumatol"},{"key":"1264_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar\u00a0A, Gensler\u00a0LS, Kay\u00a0J et al (2019) A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71:1101\u20131111","journal-title":"Arthritis Rheumatol"},{"key":"1264_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar\u00a0A, Gensler\u00a0LS, Sieper\u00a0J et al (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71:258\u2013270","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1264_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar\u00a0A, Sliwinska-Stanczyk\u00a0P, Xu\u00a0H et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013","journal-title":"Ann Rheum Dis"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","volume":"75","author":"A Deodhar","year":"2016","unstructured":"Deodhar\u00a0A, Strand\u00a0V, Kay\u00a0J et al (2016) The term \u201enon-radiographic axial spondyloarthritis\u201c is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 75:791\u2013794","journal-title":"Ann Rheum Dis"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar\u00a0A, Van Der Heijde\u00a0D, Gensler\u00a0LS et al (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a\u00a0randomised, placebo-controlled trial. Lancet 395:53\u201364","journal-title":"Lancet"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados\u00a0M, Van Der Heijde\u00a0D, Sieper\u00a0J et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a\u00a0multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66:2091\u20132102","journal-title":"Arthritis Rheumatol"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","volume":"73","author":"H Haibel","year":"2014","unstructured":"Haibel\u00a0H, Fendler\u00a0C, Listing\u00a0J et al (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a\u00a0double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73:243\u2013246","journal-title":"Ann Rheum Dis"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel\u00a0H, Rudwaleit\u00a0M, Listing\u00a0J et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a\u00a0twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58:1981\u20131991","journal-title":"Arthritis Rheum"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/ard.2011.150680","volume":"71","author":"KG Hermann","year":"2012","unstructured":"Hermann\u00a0KG, Baraliakos\u00a0X, Van Der Heijde\u00a0DM et\u00a0al (2012) Descriptions of spinal MRI lesions and definition of a\u00a0positive MRI of the spine in axial spondyloarthritis: a\u00a0consensual approach by the ASAS\/OMERACT MRI study group. Ann Rheum Dis 71:1278\u20131288","journal-title":"Ann Rheum Dis"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe\u00a0R, Braun\u00a0J, Deodhar\u00a0A et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a\u00a0double-blind randomised placebo-controlled Phase 3\u00a0study. Ann Rheum Dis 73:39\u201347","journal-title":"Ann Rheum Dis"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park\u00a0W, Yoo\u00a0DH, Miranda\u00a0P et al (2017) Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 76:346\u2013354","journal-title":"Ann Rheum Dis"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy\u00a0D, Hermann\u00a0KG, Callhoff\u00a0J et al (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a\u00a028-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73:817\u2013823","journal-title":"Ann Rheum Dis"},{"key":"1264_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","volume":"57","author":"D Poddubnyy","year":"2018","unstructured":"Poddubnyy\u00a0D, Sieper\u00a0J (2018) What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology (Oxford) 57:1145\u20131150","journal-title":"Rheumatology (Oxford)"},{"key":"1264_CR26","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3899\/jrheum.110070","volume":"38","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy\u00a0D, Vahldiek\u00a0J, Spiller\u00a0I et\u00a0al (2011) Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J\u00a0Rheumatol 38:2452\u20132460","journal-title":"J Rheumatol"},{"key":"1264_CR27","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/annrheumdis-2014-207151","volume":"74","author":"D Poddubnyy","year":"2015","unstructured":"Poddubnyy\u00a0D, Van Tubergen\u00a0A, Landewe\u00a0R et al (2015) Development of an ASAS-endorsed recommendation for the early referral of patients with a\u00a0suspicion of axial spondyloarthritis. Ann Rheum Dis 74:1483\u20131487","journal-title":"Ann Rheum Dis"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/rheumatology\/kez090","volume":"58","author":"I Redeker","year":"2019","unstructured":"Redeker\u00a0I, Callhoff\u00a0J, Hoffmann\u00a0F et al (2019) Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford) 58:1634\u20131638","journal-title":"Rheumatology (Oxford)"},{"key":"1264_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, Haibel\u00a0H, Baraliakos\u00a0X et\u00a0al (2009) The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort. Arthritis Rheum 60:717\u2013727","journal-title":"Arthritis Rheum"},{"key":"1264_CR30","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, Jurik\u00a0AG, Hermann\u00a0KG et\u00a0al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a\u00a0consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis 68:1520\u20131527","journal-title":"Ann Rheum Dis"},{"key":"1264_CR31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit\u00a0M, Khan\u00a0MA, Sieper\u00a0J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 52:1000\u20131008","journal-title":"Arthritis Rheum"},{"key":"1264_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.21619","volume":"54","author":"M Rudwaleit","year":"2006","unstructured":"Rudwaleit\u00a0M, Metter\u00a0A, Listing\u00a0J et\u00a0al (2006) Inflammatory back pain in ankylosing spondylitis: a\u00a0reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54:569\u2013578","journal-title":"Arthritis Rheum"},{"key":"1264_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.2003.011247","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit\u00a0M, Van Der Heijde\u00a0D, Khan\u00a0MA et\u00a0al (2004) How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63:535\u2013543","journal-title":"Ann Rheum Dis"},{"key":"1264_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit\u00a0M, Van Der Heijde\u00a0D, Landewe\u00a0R et\u00a0al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25\u201331","journal-title":"Ann Rheum Dis"},{"key":"1264_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, Van Der Heijde\u00a0D, Landewe\u00a0R et\u00a0al (2009) The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"1264_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper\u00a0J, Braun\u00a0J, Kay\u00a0J et al (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a\u00a0phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74:1051\u20131057","journal-title":"Ann Rheum Dis"},{"key":"1264_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper\u00a0J, Lenaerts\u00a0J, Wollenhaupt\u00a0J et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1. Ann Rheum Dis 73:101\u2013107","journal-title":"Ann Rheum Dis"},{"key":"1264_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper\u00a0J, Porter-Brown\u00a0B, Thompson\u00a0L et al (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73:95\u2013100","journal-title":"Ann Rheum Dis"},{"key":"1264_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/ard.2004.028753","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper\u00a0J, Rudwaleit\u00a0M (2005) Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 64:659\u2013663","journal-title":"Ann Rheum Dis"},{"key":"1264_CR40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2012-201777","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper\u00a0J, Srinivasan\u00a0S, Zamani\u00a0O et\u00a0al (2013) Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72:1621\u20131627","journal-title":"Ann Rheum Dis"},{"key":"1264_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","volume":"65","author":"J Sieper","year":"2013","unstructured":"Sieper\u00a0J, Van Der Heijde\u00a0D (2013) Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 65:543\u2013551","journal-title":"Arthritis Rheum"},{"key":"1264_CR42","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper\u00a0J, Van Der Heijde\u00a0D, Dougados\u00a0M et al (2015) A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 67:2702\u20132712","journal-title":"Arthritis Rheumatol"},{"key":"1264_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper\u00a0J, Van Der Heijde\u00a0D, Dougados\u00a0M et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a\u00a0randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"1264_CR44","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/ard.2008.101501","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper\u00a0J, Van Der Heijde\u00a0D, Landewe\u00a0R et\u00a0al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a\u00a0real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis 68:784\u2013788","journal-title":"Ann Rheum Dis"},{"key":"1264_CR45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"IH Song","year":"2010","unstructured":"Song\u00a0IH, Heldmann\u00a0F, Rudwaleit\u00a0M et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a\u00a0twenty-four-week clinical trial. Arthritis Rheum 62:1290\u20131297","journal-title":"Arthritis Rheum"},{"key":"1264_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/annrheumdis-2012-201926","volume":"72","author":"IH Song","year":"2013","unstructured":"Song\u00a0IH, Heldmann\u00a0F, Rudwaleit\u00a0M et al (2013) One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a\u00a0flare. Ann Rheum Dis 72:305\u2013306","journal-title":"Ann Rheum Dis"},{"key":"1264_CR47","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/ard.2010.139667","volume":"70","author":"IH Song","year":"2011","unstructured":"Song\u00a0IH, Hermann\u00a0K, Haibel\u00a0H et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a\u00a048-week randomised controlled trial. Ann Rheum Dis 70:590\u2013596","journal-title":"Ann Rheum Dis"},{"key":"1264_CR48","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D Van Der Heijde","year":"2018","unstructured":"Van Der Heijde\u00a0D, Cheng-Chung Wei\u00a0J, Dougados\u00a0M et al (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a\u00a0phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392:2441\u20132451","journal-title":"Lancet"},{"key":"1264_CR49","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde\u00a0D, Ramiro\u00a0S, Landewe\u00a0R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991","journal-title":"Ann Rheum Dis"},{"key":"1264_CR50","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D Van Der Heijde","year":"2019","unstructured":"Van Der Heijde\u00a0D, Song\u00a0IH, Pangan\u00a0AL et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394:2108\u20132117","journal-title":"Lancet"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01264-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01264-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01264-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T12:10:58Z","timestamp":1675512658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01264-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01264-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"18 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Sieper hat Honorare f\u00fcr Beratung und f\u00fcr Vortr\u00e4ge von folgenden Firmen erhalten: Abbvie, Lilly, Merck, Novartis, UCB, Pfizer. J.\u00a0Braun hat Honorare f\u00fcr Beratung und f\u00fcr Vortr\u00e4ge von folgenden Firmen erhalten: Abbvie, Amgen, Biogen, Celltrion, Fresenius, GlaxoSmithKline, Gilead, Hexal, Janssen, Lilly, MSD, Novartis and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}